Dear Friends and Investors:
Please join us for a Private Investor dinner on October 10, at 5:30pm EDT featuring 20/20 GeneSystems, Inc.
About 20/20 GeneSystems:
20/20 GeneSystems, Inc. is a clinical laboratory test developer based in Maryland with a primary focus on AI-powered blood tests for early cancer detection. We are currently the #2 market leader in the U.S. for multi-cancer early detection (MCED) blood tests. Our flagship product, OneTest™ for Multiple Cancers, is seeing rapid adoption in the MCED marketplace with ten consecutive quarters of sales growth.
Minimum investment is $100,000.
Key Highlights:
· 10 consecutive quarters of cancer testing revenue growth w/ line-of-sight to profitability
· Huge Market Potential: Medicare reimbursement for MCEDs expected by 2028 opening the door to a $2 billion revenue opportunity for OneTest
· Sophisticated Shareholder Base: Including Fujifilm (via acquisition), PingAn Ventures, Morgan Stanley (via Acquisition), Brevet Capital, Keiretsu Capital, and leading Family Offices
· IPO Ready w/ PCAOB audits, board processes, etc.
· $5M+ in research grants/contracts from National Cancer Institute (NCI) and other government agencies.
· Ranked #134 on 2023 Inc. 5000 list of the “Fastest Growing Companies in America” (#1 in Maryland)
· Team has 100+ years of experience in diagnostics and life sciences. Multiple big exits in diagnostics and MedTech by management team and board
· New longevity blood test to launch this year
Opportunity:
20/20 offers a very unique investment opportunity combining the big upside and impact of biotech coupled with a strong likelihood of near-term ROI due to our commercial traction and large, growing addressable market. With a proven track record of revenue growth, strong partnerships, and market leadership, 20/20 is poised to capture a large share of the growing MCED market. By offering a more affordable, accessible, and accurate blood test for multiple cancers, 20/20 is creating a new standard of care that can benefit millions of people worldwide.
The Investment / Investor Returns:
We are raising $10 million in two tranches: a $3 million tranche with a royalty repayment add-on followed by $7 million tranche. Investors in this round can look forward to relatively quick exits as we are an early and successful entrant into a market that many large diagnostics and lab companies will seek to enter ahead of Medicare reimbursement in 2028. 20/20 is IPO ready with public company audits completed since 2019 and the requisite Board processes in place should we decide to go public when the small cap markets rebound, as expected, in 2025.
Location
Tysons Plaza Conference Center
First Floor Main Lobby (entrance is adjacent to American Prime Restaurant)
1420 Spring Hill Road
McLean, VA, 22102
If you would like more information such as the Company’s executive summary and/or investment deck, please email Skylar Rallison at srallison@opus8.com.
We look forward to seeing you on October 10!
We will provide a confirmation email and a calendar invitation after you register.
Your attendance will be subject to client review and availability.
Thanks much and all the best,
The Opus8 Team
